In this work, the acute and subchronic toxicities of desaminotyrosine (DAT) by oral administration in SD rats and its effects on the intestinal microflora were investigated. The acute toxicity test showed that DAT is a low-toxic substance with a LD50 of 3129 mg/kg. The subchronic toxicity test showed that DAT has no toxicity at a low dose (125 mg/kg/day). However, DAT exhibited obvious toxicities to food intake, liver, kidney, and lung at higher dose (250 mg/kg/day and 500 mg/kg/day). DAT inhibited the food intake of rats in a dose-dependent manner. Serum biochemical analysis showed that DAT can increase the serum glucose level of rats. Fecal microbiota analysis showed that DAT treatment can significantly change the intestinal microflora of rats, the dose of 125 mg/kg/day has the most significant effect on the diversity of intestinal microbiota. In daily application, the side effects caused by DAT might be gastrointestinal irritation, weight loss, liver or kidney injury, and blood sugar elevation. Based on our study, the no-observed-adverse-effect level (NOAEL) of DAT is 125 mg/kg BW/day for rats.
Bacteria/drug effects , Gastrointestinal Microbiome/drug effects , Phenylpropionates/toxicity , Administration, Oral , Animals , Bacteria/growth & development , Biomarkers/blood , Blood Glucose/drug effects , Blood Glucose/metabolism , Dose-Response Relationship, Drug , Dysbiosis , Eating/drug effects , Female , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Lethal Dose 50 , Liver/drug effects , Liver/metabolism , Liver/pathology , Lung/drug effects , Lung/metabolism , Lung/pathology , Male , No-Observed-Adverse-Effect Level , Phenylpropionates/administration & dosage , Rats, Sprague-Dawley , Risk Assessment , Toxicity Tests, Subchronic , Weight Gain/drug effects
